Edgestream Partners’s Vaxcyte PCVX Stock Holding History

Edgestream Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,771	Closed	-$1.11M	–	1098
2025 Q3	$1.11M	Sell	30,771 -18,747	-38%	-$621K	0.03%	614
2025 Q2	$1.61M	Buy	+49,518	New	+$1.62M	0.04%	567
2025 Q1	–	Sell	-3,586	Closed	-$294K	–	1000
2024 Q4	$294K	Buy	+3,586	New	+$356K	0.01%	762
2024 Q1	–	Sell	-17,706	Closed	-$1.11M	–	970
2023 Q4	$1.11M	Buy	+17,706	New	+$920K	0.08%	411

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Edgestream Partners's PCVX Position: Q4 2025 in Review

Edgestream Partners sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 30,771 shares — an estimated $1.11M sold.

Edgestream Partners first reported a position in PCVX in Q4 2023 and held it in 4 quarters. The position peaked at $1.61M in Q2 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Edgestream Partners reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Edgestream Partners sold 30,771 Vaxcyte shares in Q4 2025, an estimated $1.11M.
Edgestream Partners first reported a position in Vaxcyte in Q4 2023 and held it in 4 quarters.
Edgestream Partners's Vaxcyte position peaked at $1.61M in Q2 2025.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Edgestream Partners's 13F filing for Q4 2025, filed 13 Feb 2026.